No Data
CCORF Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $167
Neurocrine Biosciences to Participate at Investor Conferences in November
Stifel Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $166
Mid-cap Stocks With 'Significant Scope' to Upside – WF
Neurocrine Biosciences Presents New Data on INGREZZA (Valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia
Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA (Valbenazine) Capsules
No Data
No Data